Table 2: Prevalence values of the various T-cell subsets in the examined patient groups and controls.

CD4CD4/CD45RACD4/CD45ROCD4/CD69CD4/HLADRCD4/CD25CD8CD8/CD45RACD8/CD45ROCD8/HLADRCD8/CD69Th1Th2Th17Treg

Anti-TNF respondersMedian25.903.3747.151.637.181.1610.705.6912.856.020.9521.008.032.815.89
25% percentile17.431.5420.680.464.440.565.392.275.1732.630.4616.707.142.254.34
75% percentile33.938.4663.852.8459.621.5219.3022.0017.009.742.1523.789.353.266.85

Anti-TNF nonrespondersMedian40.8a4.1353.901.314.33a1.7112.807.189.4804.101.2718.408.193.295.80
25% percentile24.502.5522.101.072.391.096.002.083.5501.200.596.906.7401.414.64
75% percentile44.9014.0062.502.706.916.3924.7035.2015.405.412.0121.6011.204.407.21

aIL-6R respondersMedian35.4a3.0240.004.14a,b5.354.38a5.71a,b4.9610.702.884.47a,b5.48a,b12.50a5.01a,b4.75
25% percentile26.61.528.6201.463.321.504.002.017.3701.642.253.048.5403.954.08
75% percentile47.308.3752.808.107.165.358.1237.7014.805.1911.5016.0014.405.875.65

Newly diagnosed untreated RA patientsMedian43.9a46.55a,b,c48.602.723.47a4.57a12.40c64.80a,b,c28.25a,b,c2.772.59a,b12.15a9.251.76c3.14a,b,c
25% percentile37.0534.9037.252.362.973.199.7857.4821.051.841.7710.208.841.612.81
75% percentile62.0354.2361.633.514.584.8620.0574.3334.153.983.3814.7011.001.983.66

Healthy controlsMedian41.55a52.65a,b,c41.552.42.80a,c7.13a,b,c,d19.64a,b,c69.20a,b,c23.65a,b,c2.3a1.88c10.75a5.79a,b,c,d1.04a,b,c5.17d
25% percentile37.549.1535.8751.842.476.1415.7259.7715.81.651.379.224.850.784.44
75% percentile43.6562.63849.42.853.887.7924.1275.7728.22.923.0812.377.091.195.91

Numbers indicate the median percentages and 25% and 75% percentile values within the whole T-cell population (CD4 and CD8 cells), or within CD4 cells (Th1, Th2, Th17, Treg, and ratios), or for the other markers within the CD4 or CD8 cells, as indicated. a versus anti-TNF responder, b versus anti-TNF nonresponder, c versus anti-IL-6 receptor responder, d versus newly diagnosed untreated RA patients. TNF: tumor necrosis factor alpha; IL-6R: interleukin-6 receptor.